Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Gimema, Working"'
Autor:
Francesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, Nicoletta Testoni, Angela Poerio, Marilina Amabile, Massimo Breccia, Tamara Intermesoli, Francesco Iuliano, Giovanna Rege-Cambrin, Mario Tiribelli, Maurizio Miglino, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Gianantonio Rosti, Michele Baccarani, on behalf of the GIMEMA Working Party on CML
Publikováno v:
Haematologica, Vol 93, Iss 5 (2008)
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we u
Externí odkaz:
https://doaj.org/article/e5afe5a76abf48f0ba310e69e2960d53
Autor:
Iacobucci, I, Saglio, Giuseppe, Rosti, G, Testoni, N, Pane, F, Amabile, M, Poerio, A, Soverini, S, Bassi, S, Cilloni, Daniela, Bassan, R, Breccia, M, Lauria, F, Izzo, B, Merante, S, Frassoni, F, Paolini, S, Montefusco, E, Baccarani, M, Martinelli, G, Gimema, Working, PARTY ON CHRONIC MYELOID LEUKEMIA
Publikováno v:
Clinical cancer research
12 (2006): 3037–3042. doi:10.1158/1078-0432.CCR-05-2574
info:cnr-pdr/source/autori:Iacobucci I, Saglio G, Rosti, G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Marente S, Frassoni F, Paolini S, Montefusco E, Baccarini M, MArtinelli G, Ginema Working party/titolo:Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients/doi:10.1158%2F1078-0432.CCR-05-2574/rivista:Clinical cancer research (Print)/anno:2006/pagina_da:3037/pagina_a:3042/intervallo_pagine:3037–3042/volume:12
12 (2006): 3037–3042. doi:10.1158/1078-0432.CCR-05-2574
info:cnr-pdr/source/autori:Iacobucci I, Saglio G, Rosti, G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Marente S, Frassoni F, Paolini S, Montefusco E, Baccarini M, MArtinelli G, Ginema Working party/titolo:Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients/doi:10.1158%2F1078-0432.CCR-05-2574/rivista:Clinical cancer research (Print)/anno:2006/pagina_da:3037/pagina_a:3042/intervallo_pagine:3037–3042/volume:12
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL transcripts. CCgR is durable in the majority of patients but relapse occurs in a s
Autor:
Mauro Francesca, R, Molica, Stefano, Laurenti, Luca, Cortelezzi, Agostino, Carella Angelo, M., Zaja, Francesco, Chiarenza, Annalisa, Angrilli, Francesco, Nobile, Francesco, Marasca, Roberto, Musolino, Caterina, Brugiatelli, Maura, Piciocchi, Alfonso, Vignetti, Marco, Fazi, Paola, Gentile, Giuseppe, De Propris Maria, S., Starza Irene Della, Marinelli, Marilisa, Chiaretti, Sabina, Del Giudice Ilaria, Nanni, Mauro, Albano, Francesco, Cuneo, Antonio, Guarini, Anna, Foà, Robin, per il gruppo GIMEMA Working Party Chronic Lymph, Massaia, M.
In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b4ccb24b6d738dc253957d1446622f
https://hdl.handle.net/11380/1081827
https://hdl.handle.net/11380/1081827
Autor:
SOVERINI, SIMONA, COLAROSSI, SABRINA, GNANI, ALESSANDRA, ROSTI, GIANANTONIO, CASTAGNETTI, FAUSTO, POERIO, ANGELA, IACOBUCCI, ILARIA, AMABILE, MARILINA, BACCARANI, MICHELE, MARTINELLI, GIOVANNI, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia
Purpose: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients. Experimental Design: Using denaturing high-performance liquid chromatography and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6ca62e5cfbf4dcb7dfb32271a214cf7
http://hdl.handle.net/11588/108687
http://hdl.handle.net/11588/108687
Autor:
Zaccaria, A, Testoni, N, Valenti, Am, Luatti, S, Tonelli, M, Marzocchi, G, Cipriani, R, Baldazzi, C, Giannini, B, Stacchini, M, Gamberini, C, Castagnetti, F, Rosti, G, Azzena, A, Cavazzini, Francesco, Cianciulli, Am, Dalsass, A, Donti, E, Giugliano, E, Gozzetti, A, Grimoldi, Mg, Ronconi, S, Santoro, A, Spedicato, F, Zanatta, L, Baccarani, M, GIMEMA Working Party on, C. M. L.
Additional chromosome abnormalities (ACAs) occur in less than 10% of cases at diagnosis of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). In some cases, on the basis of the persistence of the ACAs in Ph-negative cells after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532b58a4912c9e64d64394c36699fbbf
http://hdl.handle.net/11391/616897
http://hdl.handle.net/11391/616897
Autor:
PALANDRI, FRANCESCA, IACOBUCCI, ILARIA, CASTAGNETTI, FAUSTO, BACCARANI, MICHELE, Quarantelli F, Cilloni D, GIMEMA Working Party on C.M.L.
Publikováno v:
Haematologica. 92:1579-1580
CML patients who obtain a complete cytogenetic response (CCgR) may harbor different degrees of molecular disease, which are associated with different progression-free survival. We have compared the pattern and the magnitude of the molecular response
Autor:
Palandri, F, Castagnetti, F, Testoni, N, Alimena, G, Breccia, M, Levato, F, Specchia, G, Martino, B, Rege-Cambrin, G, Miglino, M, Saglio, G, Pane, F, Martinelli, G, Baccarani, M, Rosti, G, on behalf of the GIMEMA Working Party on CML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3686::a968287e8ff3d94c3c6782aad7e513d0
https://hdl.handle.net/11573/1663716
https://hdl.handle.net/11573/1663716
Autor:
Palandri, F, Castagnetti, F, Testoni, N, Luatti, S, Marzocchi, G, Bassi, S, Breccia, M, Alimena, G, Pungolino, E, Rege Cambrin, G, Varaldo, R, Miglino, M, Specchia, G, Zuffa, E, Ferrara, F, Bocchia, M, Saglio, Giuseppe, Pane, F, Alberti, D, Martinelli, G, Baccarani, M, Rosti, G, GIMEMA Working Party on Chronic Myeloid Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______970::caffac2669e608da7242b18d4a26dc34
http://hdl.handle.net/2318/95798
http://hdl.handle.net/2318/95798
Autor:
Palandri, F, Iacobucci, I, Soverini, S, Castagnetti, F, Poerio, A, Testoni, N, Alimena, G, Breccia, M, Rege-Cambrin, G, Tiribelli, M, Varaldo, R, Abruzzese, E, Martino, B, Luciano, L, Pane, F, Saglio, G, Martinelli, G, Baccarani, M, Rosti, G, on behalf of the GIMEMA Working Party on CML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3686::d9ce1763ff890f47520be8212f26f53b
https://hdl.handle.net/11573/1663735
https://hdl.handle.net/11573/1663735